When the plan to acquire Zapata was announced in June the pr outlined a plan to emerge from reorganization free of debt, and with the full support of DMRJ.
We now know that reorganization plan was CH 11 . We also know that Gregg Donnenfeld, the COO of Zapata, is or was SVP at DMRJ.
$117m from L3 less $90m liabilities less $5.7m debtor in place loan less 10% change in control payout to Bill & the boys leaves less than the the $35 m needed to do the Zapata deal. But it would be doable if DMRJ were to accept only $78m for the unsecured debt and convert the secured debt (preferred shares) into 100m shares, providing an additional $12m to fund the Zapata acquisition.
Now shareholders are left thinking that a vote to exchange our 47% equity stake in Implant Sciences Corp for a 10% equity stake in Zapata looks pretty good. Just hold your noses and vote for whichever stinks less. Capiche?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.